AIM ▼ -8.3% - AIM ImmunoTech Inc. $AIM - AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 AIM ImmunoTech shares fell 8.3% despite the company securing expanded patent protection for its Ampligen drug candidate covering Long COVID treatment in Europe and the United Kingdom through 2041. The decline suggests investors may have viewed the patent expansion as insufficient to offset broader concerns about the company's pipeline or commercial prospects. 02-SEP-2026 08:43 AM ET